Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
In the AI drug discovery field, co-creation projects and DDAIF Innovation Bridge projects accumulated, while revenue increased in the DX business. In the risk management business, cancellations by major customers, the time required to acquire new projects, cancellations of projects for private-sector companies, and the concentration of public-sector projects in the second half of the fiscal year reduced revenue. Operating income was affected by growth investments, including the expansion of research personnel in the Life Science AI business, upfront investments such as hiring in the DX business, and the decline in revenue from the risk management business.
No applicable matters. There are no notes regarding the going concern assumption.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥1,632 million (YoY +5.6%) |
| Operating profit | ¥-179 million |
| Ordinary income | ¥-138 million |
| Profit attributable to owners of the parent | ¥-105 million |
| Net income per share | −¥2.69 |
| Equity ratio | End of the current fiscal period 40.3 / End of previous period 39.7 |
| Total assets | ¥8,828 million |
| Net assets | ¥3,745 million |
| Full-year earnings forecast | Net Sales ¥7,600 million (YoY -0.6%) / Operating profit ¥300 million (YoY -59.4%) / Ordinary income ¥250 million (YoY -63.0%) / Net income ¥150 million (YoY -72.4%) |
| Revision to Earnings Forecast | No revision → No revision（No） |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | Life Science AI business ¥139,145 thousand (YoY +29.2%), Risk management business ¥826,821 thousand (YoY -18.6%), DX Business ¥694,945 thousand (YoY +64.4%) |
| Segment profit | Life Science AI business ¥-135,177 thousand, Risk management business ¥-44,222 thousand, DX Business ¥24,757 thousand (YoY -31.8%) |
| Depreciation and amortization | ¥107,706 thousand |
| Impairment loss | Amount ¥6,358 thousand / Subject assets Not disclosed |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Gain on reversal of subscription rights to shares / Amount ¥3,722 thousand, Item Gain on reversal of foreign currency translation adjustment / Amount ¥13,380 thousand / Extraordinary loss Item Impairment Losses / Amount ¥6,358 thousand, Item Loss on Disposal of Fixed Assets / Amount ¥1,912 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. There are no notes regarding the going concern assumption. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Name of newly added company Not disclosed / Excluded Company Name Not disclosed |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 39,412,362 |
| Treasury Shares at Period-End | 230,859 |
| Factors Behind Changes in Business Performance | In the AI drug discovery field, co-creation projects and DDAIF Innovation Bridge projects accumulated, while revenue increased in the DX business. In the risk management business, cancellations by major customers, the time required to acquire new projects, cancellations of projects for private-sector companies, and the concentration of public-sector projects in the second half of the fiscal year reduced revenue. Operating income was affected by growth investments, including the expansion of research personnel in the Life Science AI business, upfront investments such as hiring in the DX business, and the decline in revenue from the risk management business. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue growth was driven by the accumulation of co-creation projects in the AI drug discovery field, including DDAIF Innovation Bridge projects, and higher revenue from the DX business. In the risk management business, cancellations by major customers, longer lead times for acquiring new projects, and cancellations of projects for private-sector companies reduced revenue, while operating income was affected by growth investments and the decline in revenue.